OBJECTIVE - To assess the prognostic value of the therapeutic response by (11)C-choline PET/CT in prostate cancer patients with biochemical recurrence in which (11)C-choline PET/CT indicated radio-guided radiotherapy.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
METHODS - The study included 37 patients initially treated with prostatectomy, who were treated due to biochemical recurrence. (11)C-choline PE/CT detected infra-diaphragmatic lymph-node involvement. All were selected for intensity modulated radiation therapy, escalating the dose according to the PET findings. One year after treatment patients underwent PSA and (11)C-choline PET/CT categorizing response (complete/partial/progression). Clinical/biochemical/image monitoring was performed until appearance of second relapse or 36 months in disease-free patients.
RESULTS - (11)C-choline PET/CT could detect lymph nodes in all 37 patients. They were 18 (48. 6%) of more than a centimetre in size and 19 (51. 3%) with no pathological CT morphology: 9 (24. 3%) with positive lymph nodes of around one centimetre and 10 (27. 0%) only less than a centimetre in size. The response by (11)C-choline PET/CT was categorised one year after radiotherapy: 16 patients (43. 2%) complete response; 15 (40. 5%) partial response, and 6 (16. 2%) progression. The response was concordant between the PSA result and (11)C-choline PET/CT in 32 patients (86. 5%), and discordant in five (13. 5%). New recurrence was detected in 12 patients (80%) with partial response, and 5 (31. 2%) with complete response. The mean time to recurrence was 9 months after partial response, and 18 months after complete response (significant difference, p<. 0001).
CONCLUSIONS - (11)C-choline PET/CT allows the selection of patients with recurrent prostate cancer candidates for radiotherapy and to plan the technique. The evaluation of therapeutic response by (11)C-choline PET/CT has prognostic significance.
Revista espanola de medicina nuclear e imagen molecular. 2016 Jan 20 [Epub ahead of print]
J R García, M Cozar, M Soler, P Bassa, E Riera, J Ferrer
Unidad PET/TC, CETIR, ERESA, Esplugues, Barcelona, España. Unidad PET/TC, CETIR, ERESA, Esplugues, Barcelona, España. , Unidad PET/TC, CETIR, ERESA, Esplugues, Barcelona, España. , Unidad PET/TC, CETIR, ERESA, Esplugues, Barcelona, España. , Unidad PET/TC, CETIR, ERESA, Esplugues, Barcelona, España. , Unidad PET/TC, CETIR, ERESA, Esplugues, Barcelona, España.